-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Former CEO Anne Wojcicki's nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe ...

WHY IT'S IMPORTANT. Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a ...

Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe after a non-profit led by the company’s co-founder and former CEO Anne Wojcicki proposed a ...

A court has approved the $305m sale of 23andMe’s assets to a nonprofit led by former 23andMe CEO Anne Wojcicki.

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...

Regeneron president says that 23andMe will help further its ‘large-scale genetics research’ for drug treatments. A bankrupt 23andMe will be sold to Regeneron Pharmaceuticals, a US-based ...